C. Mitch

发表

Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.

M. Siegel, P. Emmerson, P. Surface, 2007, Bioorganic & medicinal chemistry letters.

Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.

D. McKinzie, S. D. Kahl, M. Statnick, 2011, Journal of medicinal chemistry.

Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.

F. A. Schroeder, S. Haggarty, C. Mitch, 2013, American journal of nuclear medicine and molecular imaging.

Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

F. Bymaster, A. Fink-Jensen, C. Mitch, 1998, Brain Research.

1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.

L Jeppesen, J S Ward, F. Bymaster, 1998, Journal of medicinal chemistry.

In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist

Jodi L. Smith, P. Ornstein, Xia Li, 2017, Neuropharmacology.

Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist.

P. Emmerson, T. Suter, M. Statnick, 2003, European journal of pharmacology.

Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression.

J. F. Soriano, P. Ornstein, M. Blanco, 2016, Bioorganic & medicinal chemistry letters.

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

F. Bymaster, L. Farde, P. Suzdak, 1997 .

Effect of 4-(4-methoxy-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydropyridine, an analog of MPTP, on mouse heart norepinephrine and brain catecholamines

R. Fuller, C. Mitch, S. Quimby, 1993, Neurochemistry International.

Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.

P. Emmerson, P. Surface, J. McKinzie, 2004, European journal of pharmacology.

Muscarinic agonists as analgesics. Antinociceptive activity versus M1 activity: SAR of alkylthio-TZTP's and related 1,2,5-thiadiazole analogs.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1995, Life sciences.

Xanomeline: An Efficacious and Specific M1 Receptor Agonist — Preclinical Update

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1994 .

Novel alkoxy-oxazolyl-tetrahydropyridine muscarinic cholinergic receptor antagonists

F. Bymaster, C. Mitch, S. Quimby, 2005, Psychopharmacology.

Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, Journal of medicinal chemistry.

The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells.

F. Bymaster, C. Mitch, J. Ward, 1995, Life sciences.

Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.

F. Bymaster, A. Fink-Jensen, C. Mitch, 1998, Biochemical and biophysical research communications.

Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers?

Thomas J. Raub, Stuart Morton, C. Mitch, 2014, ACS chemical neuroscience.

Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation

B. Cohen, W. Carlezon, C. Chavkin, 2011, Molecular Pharmacology.

Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: Comparison with the distribution of mu, delta and kappa binding sites

J. Pintar, T. Suter, M. Statnick, 2005, Neuropeptides.

Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human

J. Suico, D. McKinzie, J. McKinzie, 2015, The international journal of neuropsychopharmacology.

Muscarinic antagonist activity of 3-(5-alkoxy-oxazol-2-yl)-1,2,5,6-tetrahydropyridines.

D. Wong, F. Bymaster, D. Schoepp, 1994 .

Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones.

P. Ornstein, D. Schoepp, D. Lodge, 1992, Journal of medicinal chemistry.

A cyanide promoted Michael reaction: the use of an aminonitrile as an enamine equivalent for the Michael reacton

C. Mitch, 1988 .

Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones.

P. Ornstein, D. Schoepp, D. Lodge, 1992, Journal of medicinal chemistry.

Studies directed towards the total synthesis of morphine alkaloids

C. Mitch, Davidr . Evans, D. A. Evans, 1982 .

Application of metalated enamines to alkaloid synthesis. An expedient approach to the synthesis of morphine-based analgesics

C. Mitch, D. Zimmerman, Davidr . Evans, 1980 .

Muscarinic Antagonist Activity of 3‐(5‐Alkoxy‐oxazol‐2‐yl)‐1,2,5,6‐ tetrahydropyridines.

D. Wong, F. Bymaster, D. Schoepp, 1995 .

Peptides that regulate food intake: antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization.

B. Eastwood, T. Suter, M. Statnick, 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.

D. Wong, C. Mitch, A. Takemori, 1993, Journal of medicinal chemistry.

Metabotropic Glutamate Receptor

J. F. Soriano, P. Ornstein, S. Atwell, 2016 .

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

M1 receptor agonist activity is not a requirement for muscarinic antinociception.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.

J S Ward, M L Lamb, F. Bymaster, 1992, Journal of medicinal chemistry.

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .

J S Ward, F. Bymaster, A. Pike, 1992, Journal of medicinal chemistry.

Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.

C. Mitch, D. Zimmerman, M. Cohen, 1994, Receptor.

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, The Journal of pharmacology and experimental therapeutics.

Potential role of muscarinic receptors in schizophrenia.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, Life sciences.

Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens.

F. Bymaster, K. Bemis, C. Mitch, 1993, European journal of pharmacology.

Inverse isostere strategies in the development of cholinergic agonists with multiple therapeutic potentials

F. Bymaster, Michael D B Swedberg, C. Mitch, 1997 .

Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.

D. Wong, F. Bymaster, P. Suzdak, 1997, The Journal of pharmacology and experimental therapeutics.

Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects

D. McKinzie, G. Gilmour, J. Witkin, 2017, Pharmacology Biochemistry and Behavior.

3-(3-Alkylthio- 1,2,5-thiadiazol-4-yl)- 1 -azabicycles. Structure-activity relationships for antinociception mediated by central muscarinic receptors

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1996 .

Analgesic Effects of Vedaclidine, a Mixed Agonist ‚Äì Antagonist at Muscarinic Receptor Subtypes

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2003 .

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1997, Life sciences.

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1998, European journal of pharmacology.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.

Synthesis and structural determination of stereoisomers of muscarinic ligands of the (3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicycloalkane type.

C. Mitch, J. Deeter, J. Ward, 1997, Chirality.

Synthesis and Evaluation of 11C-LY2795050 as a κ-Opioid Receptor Antagonist Radiotracer for PET Imaging

Richard E. Carson, Nabeel Nabulsi, Evan D. Morris, 2013, The Journal of Nuclear Medicine.

Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

P. Ornstein, V. Tolstikov, S. Mitchell, 2017, The Journal of Pharmacology and Experimental Therapeutics.

SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIPS OF ALKYL SUBSTITUTED ANALOGUES OF THE FUNCTIONAL M1 SELECTIVE MUSCARINIC RECEPTOR AGONIST XANOMELINE

F. Bymaster, P. Suzdak, C. Mitch, 1994 .

In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously.

J. McKinzie, M. Statnick, C. Mitch, 2007, Life sciences.

Effect of phenylpiperidine opioid antagonists on food consumption and weight gain of the obese Zucker rat.

C. Mitch, D. Zimmerman, W. Shaw, 1990, The Journal of pharmacology and experimental therapeutics.

Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.

J. F. Soriano, P. Ornstein, S. Atwell, 2016, Journal of medicinal chemistry.

Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582.

D. Sindelar, B. Eastwood, M. Statnick, 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

Effects of kappa opioid receptor agonists on attention as assessed by a 5-choice serial reaction time task in rats

D. McKinzie, M. Statnick, C. Mitch, 2007, Neuropharmacology.

Novel Functional M1 Selective Muscarinic Agonists. Synthesis and Structure→Activity Relationships of 3‐(1,2,5‐Thiadiazolyl)‐1,2,5,6‐tetrahydro‐1‐methylpyridines.

F. Bymaster, A. Pike, C. Mitch, 1992 .

Steric and electronic requirements for muscarinic receptor-stimulated phosphoinositide turnover in the CNS in a series of arecoline bioisosteres.

W. Hoss, C. Mitch, S. Quimby, 1992, Biochemical and biophysical research communications.

Direct pharmacological comparison of the muscarinic receptors mediating relaxation and contraction in the rabbit thoracic aorta.

F. Bymaster, C. Mitch, J. Ward, 1999, General pharmacology.

SAR and biological evaluation of novel trans-3,4-dimethyl-4-arylpiperidine derivatives as opioid antagonists.

M. Siegel, P. Emmerson, P. Surface, 2005, Bioorganic & medicinal chemistry letters.

An Improved Antagonist Radiotracer for the κ-Opioid Receptor: Synthesis and Characterization of 11C-LY2459989

Yiyun Huang, R. Carson, J. Ropchan, 2014, The Journal of Nuclear Medicine.

A click-chemistry based strategy for labeling an anti-phosphatidylserine (PS) antibody with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold

Yiyun Huang, R. Carson, J. Ropchan, 2014 .

P. Ornstein, S. Mitchell, G. Gilmour, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists for the Treatment of Depression

V. Tolstikov, S. Mitchell, G. Gilmour, 2017 .